 |
|
|
|
 |
|
|
| Article 1 to 10 out of 26 concerning Chemokine Therapeutics Corp.
|
-
Chemokine Therapeutics Receives Approval From Hong Kong to Commence Phase II Study in Liver Cancer
(25 Aug 2008)
Chemokine Therapeutics Corp. announced that it has received a Certificate for Clinical Trial/Medicinal Test from the Hong Kong Department of Health allowing the Company to begin a Phase II trial in liver cancer with its lead drug candidate, ...
-
Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board
(15 Aug 2008)
Chemokine Therapeutics Corp. announced that Dr. Andrew Zhu has joined the Company's Oncology Clinical Advisory Board. The Advisory Board plays an important role in guiding the CTCE-9908 clinical development program.Dr. Andrew Zhu is an attending ...
-
Chemokine Therapeutics Announces Board Changes
(23 Jul 2008)
Chemokine Therapeutics Corp. announced that Edward Taylor and Walter Korz have joined the Board of Directors. They will fill vacancies created by the resignations of Dr. Hassan Salari and Reza Bahadori. Dr. Salari has also resigned as the Company's ...
-
Chemokine Therapeutics announces issuance of U.S. patent
(04 Jul 2008)
Chemokine Therapeutics Corp., a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that it has been granted U.S. Patent No. 7,378,098.Patent No. 7,378,098 entitled "CXC ...
-
Chemokine Therapeutics Announces Final Results of CTCE-9908 Phase I/II Clinical Trial in Late Stage Cancer Patients
(16 Jun 2008)
Chemokine Therapeutics Corp. announced positive data following the successful completion of the Phase I/II clinical trial for CTCE-9908, the Company's anti-cancer drug candidate. The primary objective of this Phase I/II clinical trial was to ...
-
Chemokine Therapeutics Announces New President And Chief Executive Officer
(18 Apr 2008)
Chemokine Therapeutics Corp. announced the appointment of Walter Korz as its new President and Chief Executive Officer (CEO). Mr. Korz succeeds Bashir Jaffer who held the position as Chief Executive Officer on an interim basis since December 2007. ...
-
Chemokine Therapeutics Receives Approval From Health Canada to Commence Phase II Study in Liver Cancer
(07 Mar 2008)
Chemokine Therapeutics Corp. announced that it has received a No Objection Letter from Health Canada allowing the Company to begin a Phase II study in liver cancer with its lead drug candidate, CTCE-9908. The Company also recently received FDA ...
-
Chemokine Therapeutics Receives Approval From FDA to Commence Phase II Study
(10 Jan 2008)
Chemokine Therapeutics Corp. announced that it has received notice from the U.S. Food and Drug Administration (FDA) allowing the Company to begin a Phase II study in liver cancer with its lead drug candidate, CTCE-9908.The Phase II trial will be a ...
-
Chemokine Therapeutics Announces New Directors
(19 Dec 2007)
Chemokine Therapeutics Corp. announced that Brian Kuhn, Bernard Byrd, George Kowalchuk and Reza Bahadori have joined the Board of Directors. They will fill vacancies created by the resignations of C. Richard Piazza, Michael Evans, John Osth and ...
-
Chemokine Therapeutics Continues Patient Therapy Using CTCE-9908 and Extends Closing of Its Phase I/II Clinical Trial
(12 Dec 2007)
Chemokine Therapeutics Corp. announced that the Company is continuing to treat patients with stable disease participating in the CTCE-9908 Phase I/II clinical trial. Although enrolment was completed at the end of September 2007, three patients with ...
|
|
|
|
|
Top